Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 26 Apr 2023
Nearly a quarter of the body's sugar energy, or glucose, is consumed daily by the human brain, which also has a sweet tooth. Now, scientists from the Gladstone Institutes and UC San Francisco (UCSF) have provided fresh insight into how.
Read Full NewsPhase 3 ARISE trial results show solengepras 150 mg significantly reduced OFF time and improved motor and non-motor symptoms in Parkinson disease.
Gleeson discusses JAKPPPOT data showing the therapy met all feasibility thresholds with a markedly larger response than historic placebo in PPP.
Nemolizumab Sustains Atopic Dermatitis Skin, Itch Control Through 3 Years
Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism
1.
Body Clock Genes Tied to Prostate Radiotherapy Toxicity
2.
Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL
3.
A radiotheranostic approach designed to combat aggressive cancers
4.
New guidelines expand access to lung cancer screening, but gaps remain in reaching rural and uninsured populations
5.
Limited Benefit from New Drugs; Significant Increase in Drug Prices; AI Boost for Mammo Results.
1.
Risk Assessment of Functional Vulnerability During Long-Term Cancer Survivorship
2.
Progressive Models in Hematology for Healthcare Excellence
3.
Adjuvant Atezolizumab in TNBC: What Recent Trials Reveal About Its Role
4.
Integrated Strategies in Oncology for Modern Medicine
5.
Targeted Degraders for Lymphoma: Mechanisms, Clinical Implications, and Emerging Therapies
1.
International Conference on Oncology, Cardiology and Critical Care Policy
2.
International Conference on Innovations in Critical Care for Oncology and Cardiology
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Cancer Nursing and Hematology Support
1.
A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V
3.
Current Scenario of Cancer- Q&A Session to Close the Gap Part II
4.
Should We Use DARA Up Front As First-Line Therapy in MM?
5.
Virtual Case Study on Elephantiasis of Lower Limb- An Initiative by Hidoc Dr.
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge